Antibody sequence determinants of viral antigen specificity.

Jason S McLellan, M Gordon Joyce, Ivelin S Georgiev, Rebecca A Gillespie, Masaru Kanekiyo, Alexandra A Abu-Shmais, Matthew J Vukovich, Perry T Wasdin, Yukthi P Suresh, Toma M Marinov, Scott A Rush, Rajeshwer S Sankhala, Misook Choe

Journal: mBio 2024;15(10):e0156024

PMID: 39264172

Abstract

Throughout life, humans experience repeated exposure to viral antigens through infection and vaccination, resulting in the generation of diverse, antigen-specific antibody repertoires. A paramount feature of antibodies that enables their critical contributions in counteracting recurrent and novel pathogens, and consequently fostering their utility as valuable targets for therapeutic and vaccine development, is the exquisite specificity displayed against their target antigens. Yet, there is still limited understanding of the determinants of antibody-antigen specificity, particularly as a function of antibody sequence. In recent years, experimental characterization of antibody repertoires has led to novel insights into fundamental properties of antibody sequences but has been largely decoupled from at-scale antigen specificity analysis. Here, using the LIBRA-seq technology, we generated a large data set mapping antibody sequence to antigen specificity for thousands of B cells, by screening the repertoires of a set of healthy individuals against 20 viral antigens representing diverse pathogens of biomedical significance. Analysis uncovered virus-specific patterns in variable gene usage, gene pairing, somatic hypermutation, as well as the presence of convergent antiviral signatures across multiple individuals, including the presence of public antibody clonotypes. Notably, our results showed that, for B-cell receptors originating from different individuals but leveraging an identical combination of heavy and light chain variable genes, there is a specific CDRH3 identity threshold above which B cells appear to exclusively share the same antigen specificity. This finding provides a quantifiable measure of the relationship between antibody sequence and antigen specificity and further defines experimentally grounded criteria for defining public antibody clonality.IMPORTANCEThe B-cell compartment of the humoral immune system plays a critical role in the generation of antibodies upon new and repeated pathogen exposure. This study provides an unprecedented level of detail on the molecular characteristics of antibody repertoires that are specific to each of the different target pathogens studied here and provides empirical evidence in support of a 70% CDRH3 amino acid identity threshold in pairs of B cells encoded by identical IGHV:IGL(K)V genes, as a means of defining public clonality and therefore predicting B-cell antigen specificity in different individuals. This is of exceptional importance when leveraging public clonality as a method to annotate B-cell receptor data otherwise lacking antigen specificity information. Understanding the fundamental rules of antibody-antigen interactions can lead to transformative new approaches for the development of antibody therapeutics and vaccines against current and emerging viruses.

Address: Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Computer Science, Vanderbilt University, Nashville, Tennessee, USA.; Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.; Emerging Infectious Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Computer Science, Vanderbilt University, Nashville, Tennessee, USA.; Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.; Program in Computational Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.